Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA2373291
Max Phase: Preclinical
Molecular Formula: C112H165N25O31S5
Molecular Weight: 2518.03
Molecule Type: Protein
Associated Items:
ID: ALA2373291
Max Phase: Preclinical
Molecular Formula: C112H165N25O31S5
Molecular Weight: 2518.03
Molecule Type: Protein
Associated Items:
Canonical SMILES: CC[C@H](C)[C@H](NC(=O)[C@H](CC1CCCCC1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H]1CSSC[C@@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H]2CSSC[C@H](NC(=O)[C@H](CCC(=O)O)NC(=O)[C@@H](CCCCN)NC(=O)[C@@H](CC(=O)O)NC(=O)[C@@H](CCSC)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CO)NC(=O)[C@H](CO)NC2=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](Cc2ccc(O)cc2)C(=O)N[C@@H](Cc2ccccc2)C(=O)N1)[C@@H](C)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)O
Standard InChI: InChI=1S/C112H165N25O31S5/c1-11-59(8)90(110(165)128-80(112(167)168)43-64-46-116-69-27-19-18-26-67(64)69)136-102(157)77(41-62-24-16-13-17-25-62)127-111(166)91(60(9)141)137-101(156)74(39-57(4)5)121-99(154)78(44-65-47-115-55-117-65)124-106(161)84-52-171-170-51-68(114)92(147)129-81(48-138)105(160)134-85-53-172-173-54-86(108(163)135-89(58(6)7)109(164)126-76(42-63-29-31-66(142)32-30-63)97(152)123-75(98(153)133-84)40-61-22-14-12-15-23-61)132-94(149)71(33-34-87(143)144)119-93(148)70(28-20-21-36-113)118-100(155)79(45-88(145)146)125-95(150)72(35-37-169-10)120-96(151)73(38-56(2)3)122-103(158)82(49-139)130-104(159)83(50-140)131-107(85)162/h12,14-15,18-19,22-23,26-27,29-32,46-47,55-60,62,68,70-86,89-91,116,138-142H,11,13,16-17,20-21,24-25,28,33-45,48-54,113-114H2,1-10H3,(H,115,117)(H,118,155)(H,119,148)(H,120,151)(H,121,154)(H,122,158)(H,123,152)(H,124,161)(H,125,150)(H,126,164)(H,127,166)(H,128,165)(H,129,147)(H,130,159)(H,131,162)(H,132,149)(H,133,153)(H,134,160)(H,135,163)(H,136,157)(H,137,156)(H,143,144)(H,145,146)(H,167,168)/t59-,60+,68+,70+,71-,72+,73-,74-,75-,76+,77-,78-,79?,80-,81-,82+,83-,84-,85+,86-,89-,90-,91-/m0/s1
Standard InChI Key: ZPMGWWDLRVLVTO-LPCXYAROSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Protein | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 2518.03 | Molecular Weight (Monoisotopic): 2516.0707 | AlogP: | #Rotatable Bonds: |
Polar Surface Area: | Molecular Species: | HBA: | HBD: |
#RO5 Violations: | HBA (Lipinski): | HBD (Lipinski): | #RO5 Violations (Lipinski): |
CX Acidic pKa: | CX Basic pKa: | CX LogP: | CX LogD: |
Aromatic Rings: | Heavy Atoms: | QED Weighted: | Np Likeness Score: |
1. Kikuchi T, Kubo K, Ohtaki T, Suzuki N, Asami T, Shimamoto N, Wakimasu M, Fujino M.. (1993) Endothelin-1 analogues substituted at both position 18 and 19: highly potent endothelin antagonists with no selectivity for either receptor subtype ETA or ETB., 36 (25): [PMID:8258832] [10.1021/jm00077a013] |
Source(1):